TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25994142

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP) in high-BAT group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in high-BAT group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP) in low-BAT group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in low-BAT group
Number of subjects: 0
Study: 23449352

Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolisation (sTACE) with cisplatin 50 mg administered intrarterially 4‐6 hours before PVA embolisation, repeated 3-weekly for up to three treatments
Number of subjects: 86

Group type: COMPARATOR
Intervention: Transarterial embolisation (TAE) with polyvinyl alcohol (PVA) particles alone, repeated 3-weekly for up to three treatments
Number of subjects: 86
Study: 21053841

Group type: EXPERIMENTAL
Intervention: Cognitively stimulating activities
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 19372355

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine perineural infusion (n = 15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline infusion (n = 15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine perineural infusion
Number of subjects: 32
Study: 17074485

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (n=94)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fitness group (n=60)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (n=66)
Number of subjects: 220
Study: 15131791

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 U subcutaneously, once weekly
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 185
Study: 11465928

Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 387

Group type: COMPARATOR
Intervention: Non-BiPAP
Number of subjects: 387
Study: 9715439

Group type: EXPERIMENTAL
Intervention: Intraocular irrigation fluid with 1:1,000,000 adrenaline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (intraocular irrigation fluid without adrenaline)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Study group (intraocular irrigation fluid with adrenaline)
Number of subjects: 42
Study: 15374309

Group type: EXPERIMENTAL
Intervention: Support group programme (8 sessions of 2 hours each)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (informal monthly meetings of the Alzheimer's Society)
Number of subjects: 41
Study: 2646896

Group type: EXPERIMENTAL
Intervention: Low dose hydrochlorothiazide (HCTZ), 25 mg twice daily, with dose reduction
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: High dose hydrochlorothiazide (HCTZ), 50 mg twice daily, with dose reduction
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: High dose HCTZ plus a low or high dose of a step II drug (propranolol, clonidine or reserpine), with dose reduction
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group receiving continued treatment
Number of subjects: 606
Study: 30545702

Group type: EXPERIMENTAL
Intervention: BRILMA block (interfascial blockade of the lateral cutaneous branches of the intercostal nerves)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard post-operative analgesia (paracetamol and dexketoprofen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BRILMA block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard post-operative analgesia
Number of subjects: 0
Study: 28805175

Group type: EXPERIMENTAL
Intervention: Psycho-education and monitoring programme
Number of subjects: 238

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 238
Study: 27435514

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (250 mg bolus followed by 500 mg infusion at 20 mL/hour)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and normal saline
Number of subjects: 108
Study: 24848854

Group type: EXPERIMENTAL
Intervention: Self‐paced DVD
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Live expert‐led educational seminar
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 22200381

Group type: EXPERIMENTAL
Intervention: Lumbrical splint/general stretch
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: General splint/lumbrical stretch
Number of subjects: 124

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 124
Study: 19756505

Group type: EXPERIMENTAL
Intervention: AVP 0.033 IU/min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AVP 0.067 IU/min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 50
Study: 17951487

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (48,000 IU)
Number of subjects: 11619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11619
Study: 16336888

Group type: EXPERIMENTAL
Intervention: Endovenous photocoagulation with an 810 nm diode laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional stripping operation
Number of subjects: 20
Study: 11880827

Group type: EXPERIMENTAL
Intervention: Piroxicam fast-dissolving dosage form (2 tablets sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (2 tablets administered sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Number of subjects: 50
Study: 10592453

Group type: EXPERIMENTAL
Intervention: Norditropin((R)) SimpleXx(TM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PenMate(TM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Norditropin((R)) SimpleXx(TM) and the auto-insertion device
Number of subjects: 67
Study: 7589042

Group type: EXPERIMENTAL
Intervention: i.v. 0.2 mg moxonidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 10
Study: 2083492

Group type: EXPERIMENTAL
Intervention: Educational day-care plus family support
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Family education (less intensive intervention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study: 372593

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 202
Study: 30804667

Group type: EXPERIMENTAL
Intervention: 8-week swallowing treatment protocol including effortful swallows, Mendelsohn maneuvers, tongue‐hold swallows, supraglottic swallows, Shaker exercises and effortful pitch glides, conducted once per week with additional daily home practice.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 8-week swallowing treatment protocol
Number of subjects: 9
Study: 28011290

Group type: EXPERIMENTAL
Intervention: Specialized content knowledge workshop (50-min BLS workshop)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Common content knowledge workshop (50-min BLS workshop)
Number of subjects: 203
Study: 25796973

Group type: EXPERIMENTAL
Intervention: Hypertension patients (experimental group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 300
Study: 23815518

Group type: EXPERIMENTAL
Intervention: Natural cholesterol‐lowering supplement (NCLS) containing red yeast rice, policosanols and artichoke leaf extracts, given over 16 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Natural cholesterol‐lowering supplement (NCLS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21837954

Group type: EXPERIMENTAL
Intervention: Thulium laser vaporesection of the prostate (TmLRP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Greenlight photoselective vaporization prostatectomy (PVP)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both PVP and TmLRP
Number of subjects: 118
Study: 19626475

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 ml/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.2 ml/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 27
Study: 17908831

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) administered 1 hour before blood collection
Number of subjects: 20
Study: 15520759

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246) for 6 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11264569

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in chronic hepatitis specimens
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in cirrhosis specimens
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in hepatocellular carcinoma specimens
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence in hepatoma cells
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence in nonmalignant hepatocytes adjacent to hepatocellular carcinoma
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Statistical association between density of hepatocyte growth factor and histological activity index in chronic hepatitis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Statistical association between density of hepatocyte growth factor and grade of hepatocellular carcinoma
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of hepatocyte growth factor
Number of subjects: 90
Study: 9343029

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 5
Study: 7839785

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms.kg‐1 mixed with 15 mg 0.5% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline mixed with 15 mg 0.5% bupivacaine
Number of subjects: 40
Study: 3810831

Group type: EXPERIMENTAL
Intervention: carbonyl iron, 600 mg, three times daily for 1 week
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ferrous sulfate, 300 mg (60 mg Fe++), three times daily for 1 week
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo, three times daily for 1 week
Number of subjects: 75
Study: 29915059

Group type: EXPERIMENTAL
Intervention: Group-level data
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Individual-level data
Number of subjects: 94

Group type: COMPARATOR
Intervention: Aggregated statistical estimates
Number of subjects: 94
Study: 27296202

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 280
Study: 24731441

Group type: EXPERIMENTAL
Intervention: mCBT (guided Internet-based cognitive behavior therapy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: mIPT (guided self-help treatment based on interpersonal psychotherapy)
Number of subjects: 52
Study: 22094111

Group type: EXPERIMENTAL
Intervention: Meal anticipation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no meal anticipation)
Number of subjects: 29
Study: 15729096

Group type: EXPERIMENTAL
Intervention: Leisure intervention through five 1-hour group sessions
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 11926080

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 193
Study: 10396191

Group type: EXPERIMENTAL
Intervention: 20 mg of 5‐isosorbide mononitrate (ISMO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7572685

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study: 2381309

Group type: EXPERIMENTAL
Intervention: Constant Resistance (CR) training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 49
Study: 7027889

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 15
Study: 31376788

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min/day for 4 weeks)
Number of subjects: 12
Study: 27786406

Group type: EXPERIMENTAL
Intervention: Childhood Hodgkin International Prognostic Score (CHIPS)
Number of subjects: 1103
Study: 25108626

Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention (at least one home visit and quarterly telephone calls)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention
Number of subjects: 329
Study: 23394433

Group type: EXPERIMENTAL
Intervention: Numeric calorie label
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbolic calorie label
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie labels (general)
Number of subjects: 0
Study: 21476205

Group type: EXPERIMENTAL
Intervention: Sphygmography
Number of subjects: 135
Study: 18269596

Group type: EXPERIMENTAL
Intervention: MAS064D (Sebclair)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study: 17003087

Group type: EXPERIMENTAL
Intervention: d3/fl‐GHR genotype in short SGA patients
Number of subjects: 247

Group type: COMPARATOR
Intervention: d3/d3 genotype in ACPNH
Number of subjects: 247
Study: 12631501

Group type: EXPERIMENTAL
Intervention: Food Deprivation and Restriction (Dep/Res)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Food Deprivation without Restriction (Dep/No Res)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Food Deprivation with Restriction (No Dep/Res)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Food Deprivation without Restriction (No Dep/No Res)
Number of subjects: 40
Study: 10697029

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 plus carboplatin (AUC = 6)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 127
Study: 9375939

Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mibefradil
Number of subjects: 0
Study: 8222793

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (200 mg, bid)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Cefaclor (250 mg, tid)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 301

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 301
Study: 3532293

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg once daily
Number of subjects: 574

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 574
Study: 31609709

Group type: EXPERIMENTAL
Intervention: Antibiotic and antimycotic impregnated PICC (IP-PICC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard PICC (S-PICC)
Number of subjects: 71
Study: 30497658

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 50
Study: 26962236

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 246
Study: 24930383

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Combined groups
Number of subjects: 97
Study: 22446678

Group type: EXPERIMENTAL
Intervention: Dynamic warm-up (DWU)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Static stretching warm-up (SWU)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 20726877

Group type: EXPERIMENTAL
Intervention: Immediate withdrawal (IW)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Delayed withdrawal (DW)
Number of subjects: 25
Study: 18234203

Group type: EXPERIMENTAL
Intervention: Iron carboxymaltose (up to 3 weekly doses of 1000 mg maximum, applied in 15 min)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ferrous sulfate (100 mg twice daily for 12 weeks)
Number of subjects: 344
Study: 16158748

Group type: EXPERIMENTAL
Intervention: Bactisporin (probiotic based on Bacillus subtilis, strain 3H)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional postoperative etiotropic therapy
Number of subjects: 36
Study: 14510829

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV; 1,000 to 3,000 mg/day)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 10393285

Group type: EXPERIMENTAL
Intervention: More intensive education (MIE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Less intensive education (LIE)
Number of subjects: 100
Study: 8897037

Group type: EXPERIMENTAL
Intervention: 1 ml.kg‐1 absolute ethanol added to orange juice in a 1:6 ratio
Number of subjects: 7

Group type: COMPARATOR
Intervention: Orange juice (7 ml.kg‐1)
Number of subjects: 7
Study: 1854178

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 105

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 105
Study: 6639917

Group type: EXPERIMENTAL
Intervention: Diet with P:S value of 2.0
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet with P:S value of 1.3
Number of subjects: 20
Study: 31541874

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AUD patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 25703488

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavior Therapy (TF-CBT) + parenting classes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as usual (parenting classes)
Number of subjects: 43
Study: 24528195

Group type: EXPERIMENTAL
Intervention: Internet-based telematic system (two face-to-face and five telematic appointments)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Face-to-face appointments (seven appointments)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Internet-based telematic system
Number of subjects: 154

Group type: COMPARATOR
Intervention: Face-to-face appointments
Number of subjects: 154
Study: 21935752

Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention focusing on inhaler technique, smoking cessation, and using a COPD action plan.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention (for patients with low health literacy).
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention (for patients with higher health literacy).
Number of subjects: 99
Study: 19020859

Group type: EXPERIMENTAL
Intervention: Iron lung ventilation (ILV)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Mask ventilation (NPPV)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both techniques (ILV and NPPV)
Number of subjects: 141
Study: 17970256

Group type: EXPERIMENTAL
Intervention: Abstinence-and-work (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Work-only (n = 28)
Number of subjects: 56
Study: 15447890

Group type: EXPERIMENTAL
Intervention: 2 eggs/day (EGG period; 518 additional mg cholesterol)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Egg whites (SUB period; 0 additional mg cholesterol)
Number of subjects: 54
Study: 11279634

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 (10 to 150 microg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filgrastim (5 or 10 microg/kg as a single dose, then daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 (60‐150 microg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ro 25‐8315 and Filgrastim
Number of subjects: 0
Study: 9477750

Group type: EXPERIMENTAL
Intervention: Bassini repair
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 324
Study: 7633711

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 3923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide or placebo
Number of subjects: 3923
Study: 2540054

Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicardipine (60-120 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 989578

Group type: EXPERIMENTAL
Intervention: Serum carcinoembryonic antigen (CEA) assay
Number of subjects: 377

Group type: COMPARATOR
Intervention: Radionuclide liver scan
Number of subjects: 377
Study: 31578918

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 77